Tags

Type your tag names separated by a space and hit enter

Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Clin Infect Dis. 2006 Oct 01; 43(7):917-24.CI

Abstract

During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.

Authors+Show Affiliations

Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16941377

Citation

Bern, Caryn, et al. "Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 43, no. 7, 2006, pp. 917-24.
Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43(7):917-24.
Bern, C., Adler-Moore, J., Berenguer, J., Boelaert, M., den Boer, M., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., Rosenthal, E., Royce, C., Russo, R., Sundar, S., & Alvar, J. (2006). Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 43(7), 917-24.
Bern C, et al. Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. Clin Infect Dis. 2006 Oct 1;43(7):917-24. PubMed PMID: 16941377.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Liposomal amphotericin B for the treatment of visceral leishmaniasis. AU - Bern,Caryn, AU - Adler-Moore,Jill, AU - Berenguer,Juan, AU - Boelaert,Marleen, AU - den Boer,Margriet, AU - Davidson,Robert N, AU - Figueras,Concepcion, AU - Gradoni,Luigi, AU - Kafetzis,Dimitris A, AU - Ritmeijer,Koert, AU - Rosenthal,Eric, AU - Royce,Catherine, AU - Russo,Rosario, AU - Sundar,Shyam, AU - Alvar,Jorge, Y1 - 2006/08/28/ PY - 2005/09/29/received PY - 2006/01/18/accepted PY - 2006/8/31/pubmed PY - 2006/9/16/medline PY - 2006/8/31/entrez SP - 917 EP - 24 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 43 IS - 7 N2 - During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/16941377/Liposomal_amphotericin_B_for_the_treatment_of_visceral_leishmaniasis_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/507530 DB - PRIME DP - Unbound Medicine ER -